In Brief: Hoffmann-La Roche v. Organon Teknika
This article was originally published in The Gray Sheet
Hoffmann-La Roche v. Organon Teknika: Organon's NASBA HIV load tests do not infringe Hoffmann-La Roche patents, The District Court of The Hague, The Netherlands, confirms Sept. 12, upholding a Dec. 14, 1995 summary judgment decision by the court ("The Gray Sheet" Dec. 13, 1995, In Brief). Organon notes that "in other countries litigation between Teknika and Roche on the NASBA kit is still pending." The International Trade Commission decided July 22 to hear Roche's complaint that Organon's NASBA HIV-1 RNA QT kit infringes its U.S. patent 5,476,774 which allows precise quantification of nucleic acids ("The Gray Sheet" July 29, I&W-4)...
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.